Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511]

•Triple-negative metastatic breast cancer represents a challenging scenario.•Besides chemotherapy, several novel agents are now available in clinical practice.•A modified Delphi approach was adopted to address high-priority statements.•A set of prioritized consensus statements was provided.•Relevant/unexpected results and divisive statements were discussed by the Panel.